Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Mid Atlantic Bio Angels
AddedFeb 15, 2024
UpdatedJun 28, 2026
Mid Atlantic Bio Angels

Mid Atlantic Bio Angels

Operating

MABA: A US-based venture capital firm specializing in life science investments.

Location
New York City, NY, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Mid Atlantic Bio Angels (MABA) is a US-based venture capital firm specializing in early-stage investments in life science companies. MABA typically engages in various investment rounds, including Seed, Series A, and Series B, providing essential funding to innovative startups within the life sciences sector. The firm's focus is on fostering growth and development in companies that are poised to make significant advancements in medical and biotech fields.

Notable portfolio companies include Astrocyte Pharmaceuticals, Healionics, Immunomic Therapeutics, New View Surgical, Opsidio, PainQx, and Virion Therapeutics. MABA's founder, Yaniv Sneor, brings valuable insights into funding strategies and exit paths for young life science companies. The firm emphasizes a strategic approach to investment, leveraging its expertise to guide portfolio companies through critical growth phases. MABA also offers unique value-add services, such as mentorship and strategic advisory, to help startups navigate the complex landscape of the life sciences industry.

Mid Atlantic Bio Angels - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments16
Current Portfolio Count12
Total Portfolio Exits0

Top Investment Stages

Series Unknown7 (43.8%)
Series A4 (25.0%)
Seed2 (12.5%)
Series B2 (12.5%)
Angel1 (6.3%)

Stage Mix

Series Unknown 44%Series A 25%Seed 13%Series B 13%Angel 6%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Astrocyte Pharmaceuticals logo

Astrocyte Pharmaceuticals

Hilltop Biosciences logo

Hilltop Biosciences

New View Surgical logo

New View Surgical

Seneca Therapeutics logo

Seneca Therapeutics

Sana Health logo

Sana Health

Healionics logo

Healionics

Virion Therapeutics logo

Virion Therapeutics

Elysium Therapeutics logo

Elysium Therapeutics

Opsidio logo

Opsidio

PainQx logo

PainQx

Genome Profiling logo

Genome Profiling

Evrys Bio logo

Evrys Bio

Immunomic Therapeutics logo

Immunomic Therapeutics

Mid Atlantic Bio Angels - Similar Investment Firms

Mass Medical Angels logo

Mass Medical Angels

massmedangels.com

Life Science Angels logo

Life Science Angels

Nest.Bio Venture logo

Nest.Bio Venture

nest.bio

Mid-Atlantic Venture Funds logo

Mid-Atlantic Venture Funds

Mid Atlantic Angel Fund logo

Mid Atlantic Angel Fund

Mid-Atlantic Angel Group logo

Mid-Atlantic Angel Group

magfund.com

Bioventures Investors logo

Bioventures Investors

BioInnovation logo

BioInnovation

MedScience Ventures logo

MedScience Ventures

LifeSci Venture Partners logo

LifeSci Venture Partners

lifesciventure.com

Mission BioCapital logo

Mission BioCapital

Meda Angels logo

Meda Angels

medaangels.com

Biospring Partners logo

Biospring Partners

biospring.com

Vida Ventures logo

Vida Ventures

vidaventures.com

Hub Angels Investment Group logo

Hub Angels Investment Group

hubangels.com

Mid Atlantic Bio Angels - Classification

Also Known As
  • Mid Atlantic Bio Angels LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end